Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease

British Journal of Haematology

Volumn 97, Issue 2, 1997, Pages 466-473

  Khouri, Issa F ^a,d   Przepiorka, Donna ^a   Van Besien, Koen ^a   O'Brien, Susan ^a   Palmer, Judy L ^b   Lerner, Susan ^a   Mehra, Rakesh C ^a   Vriesendorp, Huibert M ^a   Andersson, Borje S ^a   Giralt, Sergio ^a   Körbling, Martin ^a   Keating, Michael J ^c   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Depts Hematol and Biomathematics   (United States)

^c Department of Hematology   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CLL; fludarabine; GVHD; stem cells

Indexed keywords

CYCLOSPORIN; FLUDARABINE; METHOTREXATE; TACROLIMUS;

ADULT; ARTICLE; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; STEM CELL; SUPPRESSOR CELL; TREATMENT PLANNING;

EID: 8244222296     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.272673.x     Document Type: Article

References (17)

1. Cheson, B.D., Bennett, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.R., Boldt, D.H., Kempin, S.J. & Foon, K.A. (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute Sponsored Working Group. American Journal of Hematology, 29, 152-163.
2. Gribben, J.G., Barlett-Pandite, L., Provan, A., Zwicky, C., Neuberg, D., Maddocks, A., Freedman, A.S., Soiffer, R., Ritz, J. & Nadler, L.M. (1995) Disease tree status and absence of PCR detectable minimal residual disease suggests eradication of B-cells following autologous and allogeneic BMT. Blood, 10, (Suppl. 1), 457a.
3. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
4. Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McCredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
5. Keating, M.J., O'Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M. & Freireich, E.J. (1993) Long-term follow up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 81, 2878-2884.
6. Khouri, I., Keating, M.J., Vriesendorp, H.M., Reading, C.L., Przepiorka, D., Huh, Y.O., Andersson, B., van Besien, K., Mehra, R., Giralt, S., Ippoliti, C., Marshall, M., Thomas, M.W., O'Brien, S., Robertson, L.E., Deisseroth, A.B. & Champlin, R. (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of Clinical Oncology, 12, 748-758.
7. Khouri, I.F., Reading, C., Vriesendorp, H.M., Andersson, B.S., Przepiorka, D., van Besien, K., Deisseroth, A.B. & Champlin, R.E. (1995) High-dose cyclophosphamide, total body irradiation and autologous bone marrow transplantation (BMT) for chronic lymphocytic leukemia. Autologous Marrow and Blood Transplantation; Proceedings of the Seventh International Symposium, Vol. VII (ed. by K. A. Dicke and A. Keating), pp. 219-227. The Cancer Treatment Research and Educational Institute, Arlington.
8. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood, 86, 2842-2848.
9. Michallet, M., Archimbaud, E., Bandini, G., Rowlings, P.A., Deeg, H.J., Gahrton, G., Montserrat, E., Rozman, C., Gratwohl, A. & Gale, R.P. (1996) HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Annals of Internal Medicine, 124, 311-315.
10. O'Brien, S., del Giglio, A. & Keating, M. (1995) Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85, 307-318.
11. Olerup, O. & Zetterquist, H. (1993) DR low-resolution PCR-SSP typing: a correction and an update. Tissue Antigens, 41, 55-56.
12. Przepiorka, D., Ippoliti, C., Khouri, I., Anderlini, P., Stein, L., van Besien, K., Mehra, R., Giralt, S., Gajewski, J., Fritsche, H., Deisseroth, A.B., Cleary, K., Champlin, R., Andersson, B. & Korbling, M. (1995a) Tacrolimus vs cyclosporine for prevention of acute graft-vs-host disease (GVHD) after allogeneic blood stem cell transplantation. Blood, 10, (Suppl. 1), 395a.
13. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995b) Consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825-828.
14. Rabinowe, S.N., Soiffer, R.J., Gribben, J.G., Daley, H., Freedman, A.S., Daley, J., Pesek, K., Neuberg, D., Pinkus, G., Leavitt, P.R., Spector, N.A., Grossbard, M.L., Anderson, K., Robertson, M.J., Mauch, P., Chayt-Marcus, K., Ritz, J. & Nadler, L.M. (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood, 82, 1366-1376.
15. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. & Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-230.
16. Ringdén, O., Horowitz, M.M., Sondel, P., Gale, R.P., Biggs, J.C., Champlin, R.E., Deeg, H.J., Dicke, K. Masaoka, T., Powles, R.L., Rimm, A.A., Rozman, C., Sobocinski, K.A., Speck, B., Zwann, F.E. & Bortin, M.M. (1993) Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood, 81, 1094-1101.
17. Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V., Hansen, J., Hill, R., Lum, L., Martin, P., McGuffin, R., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., Yee, G. & Donnall Thomas, E. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New England Journal of Medicine, 314, 729-735.